Avengers against cancer: A new era of nano-biomaterial-based therapeutics

Kumar, Nishant; Fazal, Sajid; Miyako, Eijiro; Matsumura, Kazuaki; Rajan, Robin

doi:10.1016/j.mattod.2021.09.020

Cited by 28 publications

(17 citation statements)

References 348 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nanomaterials can not only carry a wide range of molecular drugs but also stabilize their biological activity ( Yang et al, 2019 ) and increase their solubility in biological fluids ( Guerrini et al, 2018 ). Over the past decade, several nanoparticle-based compounds have been approved to deliver packaged or coupled therapeutics ( Kumar et al, 2021 ; Wang et al, 2022b ). Initially, these nano drug delivery vectors were used to prevent drug degradation and promote enrichment at the tumor site, thereby extending the half-life of the drug ( Wang et al, 2021 ; Xia et al, 2021 ).…”

Section: Nanoparticlesmentioning

confidence: 99%

“…Understanding how to improve the response efficiency of various immunotherapies is key to improving efficacy and managing these adverse effects. Currently, NDDS have demonstrated benefits in cancer treatment and management through good pharmacokinetics, precise targeting, and reduced side effects and drug resistance ( Kumar et al, 2021 ; Xie et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomimetic nanoparticles for tumor immunotherapy

Chen

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Currently, tumor treatment research still focuses on the cancer cells themselves, but the fact that the immune system plays an important role in inhibiting tumor development cannot be ignored. The activation of the immune system depends on the difference between self and non-self. Unfortunately, cancer is characterized by genetic changes in the host cells that lead to uncontrolled cell proliferation and evade immune surveillance. Cancer immunotherapy aims to coordinate a patient’s immune system to target, fight, and destroy cancer cells without destroying the normal cells. Nevertheless, antitumor immunity driven by the autoimmune system alone may be inadequate for treatment. The development of drug delivery systems (DDS) based on nanoparticles can not only promote immunotherapy but also improve the immunosuppressive tumor microenvironment (ITM), which provides promising strategies for cancer treatment. However, conventional nano drug delivery systems (NDDS) are subject to several limitations in clinical transformation, such as immunogenicity and the potential toxicity risks of the carrier materials, premature drug leakage at off-target sites during circulation and drug load content. In order to address these limitations, this paper reviews the trends and progress of biomimetic NDDS and discusses the applications of each biomimetic system in tumor immunotherapy. Furthermore, we review the various combination immunotherapies based on biomimetic NDDS and key considerations for clinical transformation.

show abstract

Section: Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biomimetic nanoparticles for tumor immunotherapy

Chen

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Advanced anticancer medicines, that are highly effective against targeted tumors, are multifunctional, simplistic, safe, and inexpensive. Such treatments are essential for patients who experience medicinal side effects and financial issues in typical cancer remedies 1 . Bacterial cancer therapies, employed in clinical trials, are substantially attractive for targeted cancer elimination because bacteria have promising properties that make them viable candidates for the treatment [2][3][4][5][6] .…”

Section: Introductionmentioning

confidence: 99%

Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics

Goto

Iwata

Miyako

2022

Preprint

Self Cite

View full text Add to dashboard Cite

Unveiling the different biomedical functions of tumor-resident microbiota has remained challenging for the development of advanced anticancer medicines. Here we show that isolated intratumoral bacteria with its association with natural purple photosynthetic bacteria have a high innate biocompatibility and drastic immunogenic anticancer efficacies. They preferentially grow and proliferate within targeted tumor milieu, which effectively causes immune cells to infiltrate the tumor and provoke strong anticancer responses in various syngeneic mouse models including those of colorectal cancer, sarcoma, metastatic lung cancer, and extensive drug-resistant breast cancer. Furthermore, these functional bacteria-treated mice, that exhibit excellent anticancerous responses of tumors, have significantly prolonged survival rates with effective immunological memory. Notably, light-harvesting nanocomplexes of microbial consortium of intratumoral bacteria and purple photosynthetic bacteria is capable of tumor diagnosis using bio-optical-window near-infrared light, making them useful theranostic agents for highly targeted immunological elimination of the tumor and for precisely marking tumor location.

show abstract

“…Conventional cancer therapies have intrinsic limits, such as the low water solubility of a large number of anti-tumour drugs, the high non-specificity and the emergence of multi-drug resistance (MDR) after repeated administration, which restrict their therapeutic efficacy. These limitations prompted the development and application of several biomedical technologies, such as nanomedicine, which is considered to be the medical use of nanotechnology for the diagnosis, prevention and treatment of diseases through the understanding of the biochemical, physicochemical and physiological processes involving a given pathology [2][3][4]. This description encompasses three nanotechnology areas: (1) drug delivery, consisting of the design of nanostructured biomaterials that transport and deliver therapeutic loads to the target site in a controlled manner; (2) diagnosis, focusing on the Pharmaceutics 2022, 14, 388 2 of 20 development of imaging nanosystems or nanobiosensors that identify a given pathology at a cellular or molecular level with high sensitivity; and (3) theranostics, combining the design and application of nanomaterials to determine a specific pathology, and simultaneous drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Progress and Hurdles of Therapeutic Nanosystems against Cancer

et al. 2022

View full text Add to dashboard Cite

Nanomedicine against cancer, including diagnosis, prevention and treatment, has increased expectations for the solution of many biomedical challenges in the fight against this disease. In recent decades, an exhaustive design of nanosystems with high specificity, sensitivity and selectivity has been achieved due to a rigorous control over their physicochemical properties and an understanding of the nano–bio interface. However, despite the considerable progress that has been reached in this field, there are still different hurdles that limit the clinical application of these nanosystems, which, along with their possible solutions, have been reviewed in this work. Specifically, physiological processes as biological barriers and protein corona formation related to the administration routes, designing strategies to overcome these obstacles, promising new multifunctional nanotherapeutics, and recent clinical trials are presented in this review.

show abstract

Avengers against cancer: A new era of nano-biomaterial-based therapeutics

Cited by 28 publications

References 348 publications

Biomimetic nanoparticles for tumor immunotherapy

Biomimetic nanoparticles for tumor immunotherapy

Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics

Progress and Hurdles of Therapeutic Nanosystems against Cancer

Contact Info

Product

Resources

About